iCAD Announces Proposed Public Offering of Common Stock
March 02, 2021
NASHUA, N.H.,
March 02, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (the “Company”, NASDAQ: ICAD), a
global medical technology leader providing innovative cancer detection and
therapy solutions, today announced that it intends to offer and sell shares of
its common stock in an underwritten public offering. All of the shares to be
sold in the offering will be offered by the Company. The offering is subject to
market conditions and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the offering.
In addition, the Company i... Continue reading
iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2020
February 24, 2021
Fourth Quarter Revenues of .5 Million Represented 47% Sequential
Growth Driven by 70% Growth in ProFound AI ® Product
Revenue
ProFound
AI® Product Revenue Increased 21% in the Fourth Quarter of 2020 as Compared to 2019 Fourth Quarter
Fueled by Launch
of ProFound AI ® Risk Assessment Offering
Re... Continue reading
iCAD to Report Fourth Quarter 2020 Financial Results on Wednesday, February 24
February 19, 2021
NASHUA, N.H.,
Feb. 18, 2021 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology
leader providing innovative cancer detection and therapy solutions, today
announced that it will release financial results for the fourth quarter and
year ended December 31, 2020, after the market close, and host a conference
call at 4:30pm Eastern Time on Wednesday, February 24.
Wednesday
February 24th @ 4:30pmET
Domestic:
Continue reading
iCAD to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 16, 2021
NASHUA, N.H. – February 16, 2021 - iCAD,
Inc. (NASDAQ: ICAD), a global medical technology leader
providing innovative cancer detection and therapy solutions, today announced
that Michael Klein, iCAD’s Chairman and Chief Executive Officer, will
participate in a fireside chat during the BTIG Virtual MedTech, Digital Health,
Life... Continue reading
iCAD to Participate in B. Riley Securities Virtual Oncology Investor Conference
January 19, 2021
NASHUA, N.H. – January 19, 2021 - iCAD,
Inc. (NASDAQ: ICAD), a global medical technology leader
providing innovative cancer detection and therapy solutions, today announced
that Michael Klein, iCAD’s Chairman and Chief Executive Officer, will
participate in a fireside chat at the B. Riley Securities Virtual Oncology
Investor C... Continue reading
iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
January 06, 2021
New ProFound AI risk software, offering a 2-year projected
risk score to be featured
NASHUA, N.H. – January
6, 2021 – iCAD,
Inc.
(NASDAQ: ICAD), a global medical technology leader providing innovative
cancer detection and therapy solutions, today announced that it will participate in
the 10th Annual LifeSci Partners Corporate Access
Event, January 6-8 and 11-14, 2021.
Michael Klein,
Chairman and CEO, will host 1x1 meetings and will participate in a panel, Innovat... Continue reading
iCAD Announces Renowned Neuro-Oncologist Santosh Kesari, MD, PhD to Lead Post-Market Study for Treatment of Recurrent Glioblastoma (GBM) with FDA-cleared Xoft Brain IORT Technology to Support Clinical Adoption
December 29, 2020
International
Multi-Center Study to Commence January 2021
University
of Louisville’s Trial on IORT for Large Brain Lesion Treatments Accelerating
First
European Patient Treated for Brain Metastasis with Xoft IORT System
NASHUA, N.H. – December 29, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovative cancer detection and therapy
solutions, today announced the appointment of Santosh Kesari, MD, PhD,... Continue reading
Solis Mammography Adopts iCAD’s ProFound AI Platform Powered by Panorama with Short-Term Breast Cancer Risk Assessment Solution
December 10, 2020
Agreement Positions Both Companies
for Growth; Leading-edge AI Technology to be Installed Across Largest
Independent Provider of Mammography and Breast Health Services’ Network
NASHUA, NH and DALLAS, TX – December 10, 2020
– iCAD,
Inc. (NASDAQ: ICAD),
a global medical technology leader providing innovative cancer detection and
therapy solutions, and SolisMammography, the
largest independent provider of mammography and breast health services in the
United States, today announce... Continue reading
iCAD Hosting Investor Webinar on Expanded ProFound AI Portfolio with New Breast Cancer Risk Assessment Solution
December 03, 2020
Leading Clinical Experts Discuss Advancing Personalized Breast
Cancer Screening and Detection with Newly Launched ProFound AI Risk
Added Market Growth Opportunity Presented by Pioneering AI Breast
Cancer Risk Offering
Webinar Taking Place on Monday, December 7 @ 11am ET
NASHUA, N.H. – December 3, 2020 – iCAD,
Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovativ... Continue reading
iCAD Highlights Expanded Suite of Leading Breast Health AI Solutions at Virtual RSNA 2020
November 30, 2020
Groundbreaking
ProFound AI Risk Helps Transform Breast Cancer Screening from an Age-Based Paradigm
to Risk-Adapted Precision Screening, Individualized for Each Woman
NASHUA, N.H. – November 30, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovative cancer detection and therapy
solutions, today announced that the Company is showcasing its leading Breast Health Solutions,
including the expanded ProFound AI® platform powered by Panorama, at the 106th
Scientif... Continue reading
iCAD Announces Promising Clinical Data to be Presented on Treatment of Early-Stage Breast and Gynecological Cancers at ESTRO 2020 Online Congress
November 25, 2020
Growing Body of Evidence Supports Xoft Platform Across Multiple Cancer Types
NASHUA, N.H. – November 25, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that researchers from Miguel Servet University Hospital in Zaragoza, Spain, will present new data from three clinical studies supporting the efficacy of the expanded Xoft® Axxent® Electronic Brachytherapy (eBx®) System® for the treatment o... Continue reading
iCAD Reports Over 1,000 Licenses Sold as Part of ProFound AI Sales
November 24, 2020
Significant
Percentage of Licenses Sold to Facilities with GE, Siemens, and Sites with
Multiple Vendors Including Hologic and Fuji
ProFound
AI for DBT Offers Superior Clinical Performance When Compared to Other
Commercially Available Breast AI Systems
NASHUA, N.H. – November 24, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovative cancer detection and therapy
solutions, today reported that over 1,0... Continue reading
iCAD Reports Financial Results For Third Quarter And Nine Months Ended September 30, 2020
November 05, 2020
Achieved Sequential Revenue Growth of 28% in Third
Quarter of 2020, Driven by Detection Product and Therapy Product Revenue Growth
of 44% and 251%, Respectively
Net Loss Improved by .2 million to .8 million in
the Third Quarter of 2020 as Compared to .0 million in the Third Quarter of
2019
New AI Offering Expands Focus from Current Age Based
Detection to 2 Year Risk Assessment and Personalized Screening Regimen
Continue reading
iCAD to Report Third Quarter 2020 Financial Results on Thursday, November 5
October 29, 2020
NASHUA, N.H.,
Oct. 29, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology
leader providing innovative cancer detection and therapy solutions, today
announced that it will release financial results for the third quarter ended
September 30, 2020, after the market close, and host a conference call at
4:30pm Eastern Time on Thursday, November 5.
Thursday, November 5th @ 4:30pm ET
Domestic:
800-908-8386
International:  ... Continue reading
Dense Breasts: What You Should Know
October 26, 2020
Author: JoAnn Pushkin
Breast Cancer Awareness Month is here and a good time to educate
women on an important aspect in the detection of breast cancer: breast density.
The purpose of breast cancer screening is to detect cancer earlier than it
would otherwise be found. When breast cancer is found early, it means less
aggressive treatment will be needed and survival rates are highest. Multiple
studies have proven that early detection of cancers by mammography reduces
breast cancer deaths in women aged 40 to 74.
Continue reading
New Research Presented at Virtual ASTRO Meeting Supports Xoft System for Treatment of Early-Stage Breast Cancer and Gynecological Cancers
October 23, 2020
iCAD Showcasing Expanded Xoft Platform
Including Single-Fraction IORT Solution for Brain and Early-Stage Breast Cancer
Tumors
NASHUA, N.H. – October 23, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovative cancer detection and therapy
solutions, today announced the Company will showcase the expanded platform for
the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® at the American
Society for Radiation Oncology (ASTRO) Virtual Annual
Meeting, October... Continue reading
iCAD Signs Distribution Agreement with Change Healthcare
October 20, 2020
Contract with market-leading enterprise imaging provider expands
access to ProFound AI for hospitals and imaging centers across North America
NASHUA, N.H. – October 20, 2020 - iCAD, Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovative cancer detection and therapy
solutions, today announced it has signed a distribution agreement with Change Healthcare (NASDAQ:
CHNG), a leading independent healthcare te... Continue reading
New Data Supports iCAD’s Xoft Brain IORT as Feasible Treatment for Recurrent Glioblastoma
October 19, 2020
New, Encouraging Results
and Overall Patient Survival Numbers to be Presented at European Congress of
Neurosurgery
NASHUA, N.H. – October 19, 2020 – iCAD, Inc. (NASDAQ: ICAD), a global
medical technology leader providing innovative cancer detection and therapy
solutions, today announced that new, promising clinical results supporting the Xoft®
Axxent® Electronic Brachytherapy (eBx®) System® for the treatment of recurrent
glioblastoma (GBM), wil... Continue reading
iCAD Hosting Technology Innovation Webinar on the Evolving Landscape for Treating Patients with Brain, Breast, and Rectal Cancers
October 16, 2020
Webinar Taking Place on Wednesday, October 21st @ 10am ET
NASHUA, N.H.,
Oct. 16, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology
leader providing innovative cancer detection and therapy solutions, today
announced that it will host a technology innovation webinar on the current
treatment landscape and unmet medical needs for treating cancer, on Wednesday,
October 21, 2020, at 10am Eastern Time.
The call will
feature presentations by key opinion leaders Santosh Kesari, MD, PhD, John
Wayne Cancer Center, Janie Grumley,... Continue reading
Navicent Health Adopts Profound AI for Digital Breast Tomosynthesis
October 05, 2020
Clinically
Proven Technology Enhances Breast Cancer Detection, Improves Accuracy
Navicent
Health recently announced that they have added the latest development in the
fight against breast cancer – iCAD’s Profound AI for digital breast
tomosyntheses (DBT), also known as 3D mammography – to their Mammography
Program. ProFound AI for DBT was the first artificial intelligence (AI)
software for DBT to be FDA-cleared.
DBT, also called
three-dimensional (3-D) mammography, is a... Continue reading
100 Comments